MADRID -- The novel oral cardiac myosin inhibitor aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy (HCM) better than standard beta-blocker treatment, the ...

Ninerafaxstat, Imbria’s first-in-class investigational oral therapy designed to improve the heart’s ability to produce energy efficiently, is currently being evaluated in the Phase 2b FORTITUDE-HCM ...

Some supplements, including caffeine and St. John’s wort, may worsen symptoms of oHCM and interact with heart medications.

Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...

In Part D, designed to support Phase III, dosing was determined by LVOT-G for oHCM and NT-proBNP for nHCM.

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive ...

Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac ...

This AJMC® Clinical Brief provides key information regarding the EXPLORER-HCM study (NCT03470545), the results of which were originally presented by Iacopo Olivotto, MD, at the European Society of ...

There’s no cure for obstructive hypertrophic cardiomyopathy (oHCM) — treatments focus on symptom management and preventing complications. But the landscape is changing, and more cutting-edge therapies ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...